Google_______________

Risky Sex May Be Less Likely to Occur in Bathhouses than at Home

By Liz Highleyman

Since the early years of the AIDS epidemic, public health experts and members of the gay community have debated whether bathhouses and other public sex venues should be closed to prevent the spread of HIV. While some argue that such spaces encourage unsafe sex with multiple partners, others maintain that they offer an ideal opportunity for safer sex education and provision of condoms.

As reported in the June 1, 2007 Journal of Acquired Immune Deficiency Syndromes, researchers conducted a study to assess the prevalence of high-risk sexual activity, surveying 400 patrons leaving a bathhouse catering to gay men.

Results

During their visit, 91.5% of men reported they had oral sex and 44.2% had anal sex.

11.1% reported unprotected anal intercourse, and 5.5% reported unprotected receptive anal intercourse.

In the prior 3 months, 85% of patrons reported having anal sex, which was more likely to be unprotected when it occurred in a private home or hotel as opposed to a public setting (P < 0.001).

Having unprotected anal sex at home was significantly associated with also having risky sex at the bathhouse (P < 0.001).

Conclusion

"Most men at the bathhouse engaged in oral sex rather than anal sex, and most anal sex included use of condoms," they authors concluded. "Furthermore, men were more likely to have [unprotected anal intercourse] in a private home than in any public setting. The bathhouse seems to have facilitated condom use when anal sex occurred on-site."

AIDS Research Institute, Center for AIDS Prevention Studies, University of California, San Francisco CA; Abt Associates, Cambridge, MA; Department of Family Medicine, University of Washington, Seattle, WA.

06/22/07

Reference
WJ Woods, D Binson, J Blair, and others. Probability Sample Estimates of Bathhouse Sexual Risk Behavior. JAIDS 45(2): 231-238. June 1, 2007.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Index of All HIV and AIDS
Articles by Topic ( A to Z)


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)